Treatment of Post-COVID-19 POTS by inhibiting FcRn: a phase 2 randomized, placebo controlled, double-blind, proof of concept study with efgartigimod
Event: ESC Congress 2024
Topic: Autoimmune/Chronic Inflammatory Disorders and Heart Disease
Session: Long-term impact of COVID-19: direct and indirect consequences
